• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗凝血酶1C链替代突变的多效性作用

Pleiotropic effects of antithrombin strand 1C substitution mutations.

作者信息

Lane D A, Olds R J, Conard J, Boisclair M, Bock S C, Hultin M, Abildgaard U, Ireland H, Thompson E, Sas G

机构信息

Charing Cross and Westminster Medical School, London, United Kingdom.

出版信息

J Clin Invest. 1992 Dec;90(6):2422-33. doi: 10.1172/JCI116133.

DOI:10.1172/JCI116133
PMID:1469094
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC443398/
Abstract

Six different substitution mutations were identified in four different amino acid residues of antithrombin strand 1C and the polypeptide leading into strand 4B (F402S, F402C, F402L, A404T, N405K, and P407T), and are responsible for functional antithrombin deficiency in seven independently ascertained kindreds (Rosny, Torino, Maisons-Laffitte, Paris 3, La Rochelle, Budapest 5, and Oslo) affected by venous thromboembolic disease. In all seven families, variant antithrombins with heparin-binding abnormalities were detected by crossed immunoelectrophoresis, and in six of the kindreds there was a reduced antigen concentration of plasma antithrombin. Two of the variant antithrombins, Rosny and Torino, were purified by heparin-Sepharose and immunoaffinity chromatography, and shown to have greatly reduced heparin cofactor and progressive inhibitor activities in vitro. The defective interactions of these mutants with thrombin may result from proximity of s1C to the reactive site, while reduced circulating levels may be related to s1C proximity to highly conserved internal beta strands, which contain elements proposed to influence serpin turnover and intracellular degradation. In contrast, s1C is spatially distant to the positively charged surface which forms the heparin binding site of antithrombin; altered heparin binding properties of s1C variants may therefore reflect conformational linkage between the reactive site and heparin binding regions of the molecule. This work demonstrates that point mutations in and immediately adjacent to strand 1C have multiple, or pleiotropic, effects on this serpin, leading ultimately to failure of its regulatory function.

摘要

在抗凝血酶1C链及通向4B链的多肽的四个不同氨基酸残基中鉴定出六种不同的替代突变(F402S、F402C、F402L、A404T、N405K和P407T),这些突变导致了七个独立确诊的患有静脉血栓栓塞性疾病的家族(罗斯尼、都灵、梅森拉菲特、巴黎3区、拉罗谢尔、布达佩斯5区和奥斯陆)出现功能性抗凝血酶缺乏。在所有七个家族中,通过交叉免疫电泳检测到具有肝素结合异常的变异抗凝血酶,并且在其中六个家族中血浆抗凝血酶的抗原浓度降低。其中两种变异抗凝血酶,即罗斯尼和都灵变异体,通过肝素-琼脂糖和免疫亲和层析进行了纯化,并显示在体外具有大大降低的肝素辅因子和进行性抑制剂活性。这些突变体与凝血酶之间有缺陷的相互作用可能是由于1C链靠近反应位点,而循环水平降低可能与1C链靠近高度保守的内部β链有关,这些内部β链包含被认为影响丝氨酸蛋白酶抑制剂周转和细胞内降解的元件。相比之下,1C链在空间上远离形成抗凝血酶肝素结合位点的带正电荷表面;因此,1C链变异体改变的肝素结合特性可能反映了该分子反应位点和肝素结合区域之间的构象联系。这项研究表明,1C链及其紧邻区域的点突变对这种丝氨酸蛋白酶抑制剂有多种或多效性影响,最终导致其调节功能失效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/1b09c4a50837/jcinvest00054-0292-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/4fed0082ab82/jcinvest00054-0287-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/731025b3a0a2/jcinvest00054-0287-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/127fa9ae4ff9/jcinvest00054-0287-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/25ceb7b7ecd1/jcinvest00054-0287-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/7e5ae1487368/jcinvest00054-0287-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/7afcdeed6ef5/jcinvest00054-0287-f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/3d02cb9eaaac/jcinvest00054-0287-g.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/5c045d17da98/jcinvest00054-0287-h.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/54816ece3c7f/jcinvest00054-0287-i.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/76e55a41eaf1/jcinvest00054-0287-j.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/95b74640cffc/jcinvest00054-0288-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/fc6bcb0f1163/jcinvest00054-0288-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/69f3d0377535/jcinvest00054-0289-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/4633b9ff3bd1/jcinvest00054-0289-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/a1e14ccd51ab/jcinvest00054-0289-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/64c967ddc5b1/jcinvest00054-0289-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/f054b1086a83/jcinvest00054-0290-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/dc974595f454/jcinvest00054-0290-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/764dd057e028/jcinvest00054-0290-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/83da998292f5/jcinvest00054-0292-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/1b09c4a50837/jcinvest00054-0292-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/4fed0082ab82/jcinvest00054-0287-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/731025b3a0a2/jcinvest00054-0287-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/127fa9ae4ff9/jcinvest00054-0287-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/25ceb7b7ecd1/jcinvest00054-0287-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/7e5ae1487368/jcinvest00054-0287-e.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/7afcdeed6ef5/jcinvest00054-0287-f.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/3d02cb9eaaac/jcinvest00054-0287-g.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/5c045d17da98/jcinvest00054-0287-h.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/54816ece3c7f/jcinvest00054-0287-i.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/76e55a41eaf1/jcinvest00054-0287-j.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/95b74640cffc/jcinvest00054-0288-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/fc6bcb0f1163/jcinvest00054-0288-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/69f3d0377535/jcinvest00054-0289-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/4633b9ff3bd1/jcinvest00054-0289-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/a1e14ccd51ab/jcinvest00054-0289-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/64c967ddc5b1/jcinvest00054-0289-d.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/f054b1086a83/jcinvest00054-0290-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/dc974595f454/jcinvest00054-0290-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/764dd057e028/jcinvest00054-0290-c.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/83da998292f5/jcinvest00054-0292-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/44ee/443398/1b09c4a50837/jcinvest00054-0292-b.jpg

相似文献

1
Pleiotropic effects of antithrombin strand 1C substitution mutations.抗凝血酶1C链替代突变的多效性作用
J Clin Invest. 1992 Dec;90(6):2422-33. doi: 10.1172/JCI116133.
2
Cellular and functional characterization of three recombinant antithrombin mutants that caused pleiotropic effect-type deficiency.三种导致多效性效应型缺陷的重组抗凝血酶突变体的细胞和功能特性
J Biochem. 1999 Feb;125(2):253-62. doi: 10.1093/oxfordjournals.jbchem.a022281.
3
Antithrombin and its deficiency states.抗凝血酶及其缺乏状态。
Blood Coagul Fibrinolysis. 1992 Jun;3(3):315-41. doi: 10.1097/00001721-199206000-00012.
4
Proposed heparin binding site in antithrombin based on arginine 47. A new variant Rouen-II, 47 Arg to Ser.基于精氨酸47提出的抗凝血酶中的肝素结合位点。一种新的变体鲁昂-II,47位精氨酸突变为丝氨酸。
J Clin Invest. 1988 Apr;81(4):1292-6. doi: 10.1172/JCI113447.
5
Conformational change in antithrombin induced by heparin probed with a monoclonal antibody against the 1C/4B region.用针对1C/4B区域的单克隆抗体探究肝素诱导的抗凝血酶构象变化。
Biochemistry. 1994 Apr 12;33(14):4375-83. doi: 10.1021/bi00180a035.
6
Antithrombins Southport (Leu 99 to Val) and Vienna (Gln 118 to Pro): two novel antithrombin variants with abnormal heparin binding.抗凝血酶Southport(第99位亮氨酸突变为缬氨酸)和Vienna(第118位谷氨酰胺突变为脯氨酸):两种具有异常肝素结合能力的新型抗凝血酶变体。
Br J Haematol. 1995 Mar;89(3):602-9. doi: 10.1111/j.1365-2141.1995.tb08369.x.
7
Role of the C-sheet in the maturation of N-glycans on antithrombin: functional relevance of pleiotropic mutations.C-片层在抗凝血酶 N-聚糖成熟中的作用:多效突变的功能相关性。
J Thromb Haemost. 2014 Jul;12(7):1131-40. doi: 10.1111/jth.12606. Epub 2014 Jun 19.
8
Deletion of P1 arginine in a novel antithrombin variant (antithrombin London) abolishes inhibitory activity but enhances heparin affinity and is associated with early onset thrombosis.在一种新型抗凝血酶变体(抗凝血酶伦敦)中删除P1精氨酸会消除抑制活性,但会增强肝素亲和力,并与早发性血栓形成有关。
J Biol Chem. 2003 Apr 18;278(16):13688-95. doi: 10.1074/jbc.M300062200. Epub 2003 Feb 18.
9
Introduction of a mutation in the shutter region of antithrombin (Phe77 --> Leu) increases affinity for heparin and decreases thermal stability.抗凝血酶快门区域突变(苯丙氨酸77→亮氨酸)的引入增加了对肝素的亲和力并降低了热稳定性。
Biochemistry. 2003 Sep 2;42(34):10169-73. doi: 10.1021/bi0349322.
10
Characterization of heparin binding variants of antithrombin by crossed immunoelectrophoresis in the presence of heparin.在肝素存在的情况下,通过交叉免疫电泳对抗凝血酶的肝素结合变体进行表征。
Methods Mol Med. 1999;31:297-302. doi: 10.1385/1-59259-248-1:297.

引用本文的文献

1
Full-length antithrombin frameshift variant with aberrant C-terminus causes endoplasmic reticulum retention with a dominant-negative effect.全长抗凝血酶移码变体伴有异常的 C 末端导致内质网滞留并具有显性负效应。
JCI Insight. 2022 Oct 10;7(19):e161430. doi: 10.1172/jci.insight.161430.
2
Investigation of the Differences in Antithrombin to Heparin Binding among Antithrombin Budapest 3, Basel, and Padua Mutations by Biochemical and In Silico Methods.通过生化和计算机模拟方法研究抗凝血酶布达佩斯 3、巴塞尔和帕多瓦突变体与肝素结合的差异。
Biomolecules. 2021 Apr 8;11(4):544. doi: 10.3390/biom11040544.
3
Portal Vein Thrombosis in a Patient with Hereditary Antithrombin Deficiency.

本文引用的文献

1
INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.遗传性抗凝血酶缺乏导致血栓形成倾向。
Thromb Diath Haemorrh. 1965 Jun 15;13:516-30.
2
[On the presence of neutral fats in normal and pathological human thrombocytes].[关于正常及病理性人体血小板中中性脂肪的存在情况]
Thromb Diath Haemorrh. 1963 Apr 15;9:1-11.
3
Heterogeneity of the "classical" antithrombin III deficiency.“经典型”抗凝血酶III缺乏症的异质性
一名遗传性抗凝血酶缺乏患者的门静脉血栓形成
Intern Med. 2019 Jun 15;58(12):1733-1737. doi: 10.2169/internalmedicine.2295-18. Epub 2019 Feb 25.
4
Characterisation of a type II functionally-deficient variant of alpha-1-antitrypsin discovered in the general population.在普通人群中发现的一种 II 型功能缺陷型α-1-抗胰蛋白酶的特征。
PLoS One. 2019 Jan 11;14(1):e0206955. doi: 10.1371/journal.pone.0206955. eCollection 2019.
5
Disease-causing mutations in the serpin antithrombin reveal a key domain critical for inhibiting protease activities.丝氨酸蛋白酶抑制剂抗凝血酶中的致病突变揭示了抑制蛋白酶活性的关键结构域。
J Biol Chem. 2017 Oct 6;292(40):16513-16520. doi: 10.1074/jbc.M117.787325. Epub 2017 Jul 25.
6
Cellular folding pathway of a metastable serpin.一种亚稳态丝氨酸蛋白酶抑制剂的细胞折叠途径。
Proc Natl Acad Sci U S A. 2016 Jun 7;113(23):6484-9. doi: 10.1073/pnas.1603386113. Epub 2016 May 24.
7
Antithrombin III deficiency in Indian patients with deep vein thrombosis: identification of first India based AT variants including a novel point mutation (T280A) that leads to aggregation.印度深静脉血栓形成患者的抗凝血酶III缺乏症:鉴定首个基于印度的抗凝血酶变体,包括导致聚集的新型点突变(T280A)
PLoS One. 2015 Mar 26;10(3):e0121889. doi: 10.1371/journal.pone.0121889. eCollection 2015.
8
Antithrombin Murcia (K241E) causing antithrombin deficiency: a possible role for altered glycosylation.抗凝血酶 Murcia(K241E)导致抗凝血酶缺乏症:糖基化改变的可能作用。
Haematologica. 2010 Aug;95(8):1358-65. doi: 10.3324/haematol.2009.015487. Epub 2010 Apr 30.
9
Specific interactions of serpins in their native forms attenuate their conformational transitions.丝氨酸蛋白酶抑制剂(serpins)天然形式下的特异性相互作用会减弱其构象转变。
Protein Sci. 2007 Aug;16(8):1659-66. doi: 10.1110/ps.072838107. Epub 2007 Jun 28.
10
Five novel and four recurrent point mutations in the antithrombin gene causing venous thrombosis.抗凝血酶基因中的五个新的和四个复发性点突变导致静脉血栓形成。
Int J Hematol. 2003 Jul;78(1):79-83. doi: 10.1007/BF02983246.
Thromb Haemost. 1980 Jun 18;43(2):133-6.
4
Hereditary antithrombin III deficiency: biochemical aspects.遗传性抗凝血酶III缺乏症:生化方面
Haematologia (Budap). 1984;17(1):81-6.
5
The heparin-binding site of antithrombin III. Identification of a critical tryptophan in the amino acid sequence.抗凝血酶III的肝素结合位点。氨基酸序列中一个关键色氨酸的鉴定。
J Biol Chem. 1984 Jan 25;259(2):939-41.
6
Characterization of an unusual DNA length polymorphism 5' to the human antithrombin III gene.人抗凝血酶III基因5'端一种异常DNA长度多态性的特征分析。
Nucleic Acids Res. 1983 Dec 20;11(24):8569-82. doi: 10.1093/nar/11.24.8569.
7
Antithrombin III Toyama: replacement of arginine-47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability.富山抗凝血酶III:遗传性异常抗凝血酶III中精氨酸-47被半胱氨酸取代,该抗凝血酶III缺乏肝素结合能力。
Proc Natl Acad Sci U S A. 1984 Jan;81(2):289-93. doi: 10.1073/pnas.81.2.289.
8
Molecular heterogeneity of inherited antithrombin III deficiency.遗传性抗凝血酶III缺乏症的分子异质性
N Engl J Med. 1983 Jun 30;308(26):1549-52. doi: 10.1056/NEJM198306303082601.
9
Binding of thrombin to antithrombin III.凝血酶与抗凝血酶III的结合。
Scand J Clin Lab Invest. 1969 Aug;24(1):23-7. doi: 10.3109/00365516909080127.
10
The purification and mechanism of action of human antithrombin-heparin cofactor.人抗凝血酶-肝素辅因子的纯化及其作用机制
J Biol Chem. 1973 Sep 25;248(18):6490-505.